- Home
- HTH vs MANE Comparison
HTH vs MANE Comparison
Compare HTH & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | MANE |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | HTH | MANE |
|---|---|---|
| Price | $37.13 | $104.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $37.50 | ★ $83.33 |
| AVG Volume (30 Days) | 255.7K | ★ 710.7K |
| Earning Date | 04-23-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | $58.23 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $28.92 | $36.26 |
| 52 Week High | $40.41 | $117.71 |
Technical Indicators
Market Signals| Indicator | HTH | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 62.68 |
| Support Level | $36.49 | $54.23 |
| Resistance Level | $37.30 | N/A |
| Average True Range (ATR) | 0.81 | 10.37 |
| MACD | -0.08 | 0.24 |
| Stochastic Oscillator | 34.04 | 73.18 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.